PHAT Stock News & Catalysts – Phathom Pharmaceuticals

FEATURED

Phathom Pharmaceuticals to Participate in November Investor Conferences

FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)

Summary

Nov 4, 2026, 8:00 AM ·Globe Newswire

RECENT

Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx

Potential to pay as little as $0 per fill for VOQUEZNA, plus free home delivery and prior authorization support, makes it simpler for GERD patients to get the medicine their doctor prescribed A Media Snippet

Nov 3, 2026, 8:00 AM ·Globe Newswire

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026Generated positive operating cash flow for the second

Oct 29, 2026, 7:00 AM ·Globe Newswire

Phathom Pharmaceuticals Provides Update on FDA Litigation

FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)

Oct 26, 2026, 4:00 AM ·Globe Newswire

Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA

FLORHAM PARK, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)

Oct 23, 2026, 4:00 AM ·Globe Newswire

Phathom Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide Business Update on Thursday, October 29, 2026

FLORHAM PARK, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)

Oct 19, 2026, 8:00 AM ·Globe Newswire

Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026

New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on

Oct 12, 2026, 8:00 AM ·Globe Newswire

Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

Three scientific presentations will highlight new analyses of VOQUEZNA® (vonoprazan) in GERD, including real-world patient characteristics, efficacy across BMI subgroups, and cost-effectiveness in Erosive Esophagitis

Oct 8, 2026, 8:00 AM ·Globe Newswire

Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD

Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 dataTopline results expected in the first

Sep 29, 2026, 8:00 AM ·Globe Newswire

PHAT Investors Have Opportunity to Join Phathom Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Phathom Pharmaceuticals, Inc. ("Phathom" or

Sep 16, 2026, 7:44 PM ·Business Wire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI)

Sep 1, 2026, 8:00 AM ·Globe Newswire

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- PHAT shareholders absorbed the loss when Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued FY 2026 revenue guidance with a high end of $325 million -- below Wall Street

Aug 4, 2026, 10:09 AM ·Globe Newswire

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals cut its FY 2026 revenue outlook to $310 million -- $325 million, below the roughly $332 million -- $334 million analysts expected, and PHAT shares dropped. Levi & Korsinsky is investigating

Aug 3, 2026, 10:07 AM ·Business Wire

PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals

Phathom Pharmaceuticals told investors on April 30, 2026 that it was "maintaining" its FY 2026 revenue guidance of $320 million to $345 million. Weeks later, the Company cut that outlook to $310 million to $325

Jul 31, 2026, 10:07 AM ·PRNewswire

Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals guided FY 2026 revenue as high as $345 million while building out a sales force of more than 290 representatives. The revised outlook now tops out at $325 million, and PHAT shareholders absorbed

Jul 30, 2026, 5:34 PM ·PRNewswire

Phathom Pharmaceuticals, Inc. PHAT · News